AGIO

Key TakeawaysAgios Pharmaceuticals shares fell [19%] after the FDA moved its mitapivat decision in sickle cell disease to Feb. 1, 2027.

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals is pursuing US FDA accelerated approval for mitapivat in sickle cell disease after Priority Review of Phase 3 RISE UP data showing significant hemoglobin responses in patients aged 16 and older.

Agios Pharmaceuticals (AGIO) has set November 5, 2026, for a conference call and webcast covering third quarter results and business updates, giving investors a scheduled checkpoint on this rare disease focused biotech company.

Agios Pharmaceuticals has delivered a 37.6% gain over the past 3 years. The key question now is whether that share price aligns with the sales the business is generating.

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.